We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Axonics Inc | NASDAQ:AXNX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 67.11 | 62.62 | 67.50 | 0 | 12:00:06 |
From Nov 2023 to May 2024
By Ben Glickman
Shares of Axonics rose on Monday after the company agreed be acquired for $3.7 billion in cash by Boston Scientific.
The stock was up 20% to $69.25, its highest intraday level since December 2022. Shares are up about 26% in the last year.
Boston Scientific said before the open it would pay $71 per share in cash for Axonics, which is focused on developing products to address bladder and bowel issues. Axonics will become a wholly-owned subsidiary of Boston Scientific.
The deal is expected to close in the first half of this year.
Axonics said Monday it now expects fourth-quarter revenue of $109.3 million to $109.7 million. Analysts polled by FactSet expected fourth-quarter revenue of $105.6 million.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 11:21 ET (16:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Axonics Chart |
1 Month Axonics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
